» Articles » PMID: 18483257

The Ret Receptor Tyrosine Kinase Pathway Functionally Interacts with the ERalpha Pathway in Breast Cancer

Overview
Journal Cancer Res
Specialty Oncology
Date 2008 May 17
PMID 18483257
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

A limited number of receptor tyrosine kinases (e.g., ErbB and fibroblast growth factor receptor families) have been genetically linked to breast cancer development. Here, we investigated the contribution of the Ret receptor tyrosine kinase to breast tumor biology. Ret was expressed in primary breast tumors and cell lines. In estrogen receptor (ER)alpha-positive MCF7 and T47D lines, the ligand (glial-derived neurotrophic factor) activated signaling pathways and increased anchorage-independent proliferation in a Ret-dependent manner, showing that Ret signaling is functional in breast tumor cells. Ret expression was induced by estrogens and Ret signaling enhanced estrogen-driven proliferation, highlighting the functional interaction of Ret and ER pathways. Furthermore, Ret was detected in primary cancers, and there were higher Ret levels in ERalpha-positive tumors. In summary, we showed that Ret is a novel proliferative pathway interacting with ER signaling in vitro. Expression of Ret in primary breast tumors suggests that Ret might be a novel therapeutic target in breast cancer.

Citing Articles

Kinase Plasticity in Response to Vandetanib Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast Cancer.

Kakati R, Whitman A, Haase S, Szenasi A, Thai C, Brunk E bioRxiv. 2025; .

PMID: 39975402 PMC: 11838206. DOI: 10.1101/2024.12.19.629395.


RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer.

Kindt C, Ehmsen S, Traynor S, Policastro B, Nissen N, Jakobsen M Front Oncol. 2025; 14:1497093.

PMID: 39931212 PMC: 11808005. DOI: 10.3389/fonc.2024.1497093.


Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial.

Beresford M, Casbard A, Hudson Z, Carucci M, Ingarfield K, Gee J BJC Rep. 2024; 1(1):13.

PMID: 39516358 PMC: 11523984. DOI: 10.1038/s44276-023-00016-8.


REThinking the role of the RET oncogene in breast cancer.

Di Grazia G, Conti C, Nucera S, Motta G, Martorana F, Stella S Front Oncol. 2024; 14:1427228.

PMID: 39211557 PMC: 11358597. DOI: 10.3389/fonc.2024.1427228.


RET overexpression leads to increased brain metastatic competency in luminal breast cancer.

Jagust P, Powell A, Ola M, Watson L, de Pablos-Aragoneses A, Garcia-Gomez P J Natl Cancer Inst. 2024; 116(10):1632-1644.

PMID: 38852945 PMC: 11461165. DOI: 10.1093/jnci/djae091.